Fournier gangrene—a fulminant necrosis of the fascia surrounding the genitals and perineum—is a rare and often fatal urologic emergency that disproportionally affects men at a 10:1 ratio.1 Case reports linking Fournier gangrene with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors prompted a US Food and Drug Administration warning in August 2018.2 We examined the association of the risk of hospitalization for Fournier gangrene with initiation of SGLT-2 inhibitor treatment among men.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Dave CV, Schneeweiss S, Patorno E. Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men. JAMA Intern Med. Published online September 03, 2019. doi:10.1001/jamainternmed.2019.2813
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: